TY - JOUR
T1 - Inhaled siRNA Formulations for Respiratory Diseases
T2 - From Basic Research to Clinical Application
AU - Fan, Yulin
AU - Yang, Zhijun
N1 - Funding Information:
These authors appreciate the funding support by the Innovation and Technology Commission of Hong Kong [grant number ITS/348/18FX].
Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/6/2
Y1 - 2022/6/2
N2 - The development of siRNA technology has provided new opportunities for
gene-specific inhibition and knockdown, as well as new ideas for the
treatment of disease. Four siRNA drugs have already been approved for
marketing. However, the instability of siRNA in vivo makes systemic
delivery ineffective. Inhaled siRNA formulations can deliver drugs
directly to the lung, showing great potential for treating respiratory
diseases. The clinical applications of inhaled siRNA formulations still
face challenges because effective delivery of siRNA to the lung requires
overcoming the pulmonary and cellular barriers. This paper reviews the
research progress for siRNA inhalation formulations for the treatment of
various respiratory diseases and summarizes the chemical structural
modifications and the various delivery systems for siRNA. Finally, we
conclude the latest clinical application research for inhaled siRNA
formulations and discuss the potential difficulty in efficient clinical
application.
AB - The development of siRNA technology has provided new opportunities for
gene-specific inhibition and knockdown, as well as new ideas for the
treatment of disease. Four siRNA drugs have already been approved for
marketing. However, the instability of siRNA in vivo makes systemic
delivery ineffective. Inhaled siRNA formulations can deliver drugs
directly to the lung, showing great potential for treating respiratory
diseases. The clinical applications of inhaled siRNA formulations still
face challenges because effective delivery of siRNA to the lung requires
overcoming the pulmonary and cellular barriers. This paper reviews the
research progress for siRNA inhalation formulations for the treatment of
various respiratory diseases and summarizes the chemical structural
modifications and the various delivery systems for siRNA. Finally, we
conclude the latest clinical application research for inhaled siRNA
formulations and discuss the potential difficulty in efficient clinical
application.
KW - clinical application
KW - delivery systems
KW - drug delivery barriers
KW - inhaled siRNA formulations
KW - respiratory diseases
KW - structural modification
UR - http://www.scopus.com/inward/record.url?scp=85132031993&partnerID=8YFLogxK
U2 - 10.3390/pharmaceutics14061193
DO - 10.3390/pharmaceutics14061193
M3 - Review article
AN - SCOPUS:85132031993
SN - 1999-4923
VL - 14
JO - Pharmaceutics
JF - Pharmaceutics
IS - 6
M1 - 1193
ER -
